Wall Street brokerages forecast that HTG Molecular Diagnostics Inc (NASDAQ:HTGM) will report $7.59 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for HTG Molecular Diagnostics’ earnings. The highest sales estimate is $8.40 million and the lowest is $6.77 million. HTG Molecular Diagnostics reported sales of $7.90 million in the same quarter last year, which indicates a negative year over year growth rate of 3.9%. The business is scheduled to report its next quarterly earnings report on Thursday, March 28th.
On average, analysts expect that HTG Molecular Diagnostics will report full-year sales of $21.75 million for the current year, with estimates ranging from $21.00 million to $22.50 million. For the next financial year, analysts anticipate that the firm will report sales of $27.97 million, with estimates ranging from $24.13 million to $31.80 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover HTG Molecular Diagnostics.
HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its quarterly earnings results on Thursday, November 8th. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.01. The company had revenue of $4.71 million for the quarter, compared to analysts’ expectations of $5.14 million. HTG Molecular Diagnostics had a negative return on equity of 132.67% and a negative net margin of 81.10%.
Several research analysts have issued reports on HTGM shares. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of HTG Molecular Diagnostics in a report on Friday, September 28th. ValuEngine upgraded shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating in a research report on Wednesday, August 8th. Cantor Fitzgerald reiterated a “buy” rating and set a $7.00 target price on shares of HTG Molecular Diagnostics in a research report on Friday. Finally, Zacks Investment Research upgraded shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a research report on Tuesday, August 14th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $6.25.
Large investors have recently modified their holdings of the business. FMR LLC boosted its position in shares of HTG Molecular Diagnostics by 2.9% in the 3rd quarter. FMR LLC now owns 3,588,045 shares of the medical research company’s stock valued at $18,120,000 after purchasing an additional 100,000 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of HTG Molecular Diagnostics in the 3rd quarter valued at about $1,089,000. Private Wealth Partners LLC boosted its position in shares of HTG Molecular Diagnostics by 11.1% in the 3rd quarter. Private Wealth Partners LLC now owns 1,000,000 shares of the medical research company’s stock valued at $5,050,000 after purchasing an additional 100,000 shares during the period. Granahan Investment Management Inc. MA boosted its position in shares of HTG Molecular Diagnostics by 14.1% in the 2nd quarter. Granahan Investment Management Inc. MA now owns 915,449 shares of the medical research company’s stock valued at $2,984,000 after purchasing an additional 112,928 shares during the period. Finally, Putnam Investments LLC boosted its position in shares of HTG Molecular Diagnostics by 31.4% in the 2nd quarter. Putnam Investments LLC now owns 1,387,883 shares of the medical research company’s stock valued at $4,524,000 after purchasing an additional 331,690 shares during the period. Hedge funds and other institutional investors own 50.55% of the company’s stock.
NASDAQ HTGM opened at $3.65 on Friday. The firm has a market capitalization of $118.23 million, a price-to-earnings ratio of -2.04 and a beta of 2.03. HTG Molecular Diagnostics has a 1 year low of $1.71 and a 1 year high of $5.83. The company has a current ratio of 9.50, a quick ratio of 9.29 and a debt-to-equity ratio of 0.35.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
Recommended Story: Compound Interest
Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.